Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Hai‐Yan, Yin, Kai, Zhao, Xiaotian, Ke, E‐E, Wu, Si‐Pei, Li, Yang‐Si, Zheng, Mei‐Mei, Liu, Si‐Yang Maggie, Xu, Chong‐Rui, Sun, Yue‐Li, Lin, Jia‐Xin, Bai, Xiao‐Yan, Zhang, Yi‐Chen, Zhou, Qing, Yang, Jin‐Ji, Zhong, Wen‐Zhao, Wang, Bing‐Chao, Zhang, Xu‐Chao, Zhu, Dongqin, Yang, Lingling, Ou, Qiuxiang, Wu, Yi‐Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399722/
https://www.ncbi.nlm.nih.gov/pubmed/37078460
http://dx.doi.org/10.1002/1878-0261.13439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399722/
https://www.ncbi.nlm.nih.gov/pubmed/37078460
http://dx.doi.org/10.1002/1878-0261.13439

Ejemplares similares